CoChat

Development and Progression of Renal Insufficiency With and Without Albuminuria in Adults With Type 1 Diabetes in the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study

Open access
Molitch, Mark E., Steffes, Michael, Sun, Wanjie, Rutledge, Brandy, Cleary, Patricia, de Boer, Ian H., Zinman, Bernard, Lachin, John, for the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Group · 2010 · Diabetes Care

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: This multicenter study examined the impact of albumin excretion rate (AER) on the course of estimated glomerular filtration rate (eGFR) and the incidence of sustained eGFR <60 ml/min/1.73 m2 in type 1 diabetes up to year 14 of the Epidemiology of Diabetes Interventions and Complications (EDIC) study (mean duration of 19 years in the Diabetes Control and Complications Trial [DCCT]/EDIC). RESEARCH DESIGN AND METHODS: Urinary albumin measurements from 4-h urine collections were obtained from participants annually during the DCCT and every other year during the EDIC study, and serum creatinine was measured annually in both the DCCT and EDIC study. GFR was estimated from serum creatinine using the abbreviated Modification of Diet in Renal Disease equation. RESULTS: A total of 89 of 1,439 subjects developed an eGFR <60 ml/min/1.73 m2 (stage 3 chronic kidney disease on two or more successive occasions (sustained) during the DCCT/EDIC study (cumulative incidence 11.4%). Of these, 20 (24%) had AER <30 mg/24 h at all prior evaluations, 14 (16%) had developed microalbuminuria (AER 30–300 mg/24 h) before they reached stage 3 chronic kidney disease, and 54 (61%) had macroalbuminuria (AER >300 mg/24 h) before they reached stage 3 chronic kidney disease. Macroalbuminuria is associated with a markedly increased rate of fall in eGFR (5.7%/year vs. 1.2%/year with AER <30 mg/24 h, P < 0.0001) and risk of eGFR <60 ml/min/1.73 m2 (adjusted hazard ratio 15.3, P < 0.0001), whereas microalbuminuria had weaker and less consistent effects on eGFR. CONCLUSIONS: Macroalbuminuria was a strong predictor of eGFR loss and risk of developing sustained eGFR <60 ml/min/1.73 m2. However, screening with AER alone would have missed 24% of cases of sustained impaired eGFR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc09-1098

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 A: The proportions of subjects with a history of normal AER (AER ≤30 mg/24 h), microalbuminuria (AER >30 and ≤300 mg/24 h), and macroalbuminuria (AER >300 mg/24 h or ESRD) among subjects who never developed a sustained eGFR <60 ml/min/1.73 m2 by the time of their final visit, or at the visit where a subject first presents with a sustained eGFR <60 ml/min/1.73 m2. B: Cumulative incidence of sustained eGFR <60 ml/min/1.73 m2 during the DCCT/EDIC follow-up among the 1,439 DCCT/EDIC participants.
Figure 1 A: The proportions of subjects with a history of normal AER (AER ≤30 mg/24 h), microalbuminuria (AER >30 and ≤300 mg/24 h), and macroalbuminuria (AER >300 mg/24 h or ESRD) among subjects who never developed a sustained eGFR <60 ml/min/1.73 m2 by the time of their final visit, or at the visit where a subject first presents with a sustained eGFR <60 ml/min/1.73 m2. B: Cumulative incidence of sustained eGFR <60 ml/min/1.73 m2 during the DCCT/EDIC follow-up among the 1,439 DCCT/EDIC participants.CC BY-NC-ND · PubMed Central
Figure 2 A: Estimates of the mean levels of eGFR at each DCCT-EDIC follow-up year among subjects currently with normal AER, or microalbuminuria or macroalbuminuria at that time, obtained from the general linear mixed model in Table 2. Subjects may switch from one AER category to another depending on their current AER levels at each visit. For each AER category, the estimated mean levels of eGFR are shown for intervals during which at least 20 subjects had a visit. B: Smoothed estimates of the distribution of percent change in eGFR per year while subjects were in each current AER category. The y-axis is the probability density or the derivative of the probability distribution such that the integrated area under each curve equals 1. Each patient's rate of change in eGFR while currently in each AER category is estimated from the general linear mixed model in Table 2 (the current albuminuria model). Note the range of substantially increased rates of decline in eGFR while subjects had macroalbuminuria relative to those while having normal albuminuria or microalbuminuria.
Figure 2 A: Estimates of the mean levels of eGFR at each DCCT-EDIC follow-up year among subjects currently with normal AER, or microalbuminuria or macroalbuminuria at that time, obtained from the general linear mixed model in Table 2. Subjects may switch from one AER category to another depending on their current AER levels at each visit. For each AER category, the estimated mean levels of eGFR are shown for intervals during which at least 20 subjects had a visit. B: Smoothed estimates of the distribution of percent change in eGFR per year while subjects were in each current AER category. The y-axis is the probability density or the derivative of the probability distribution such that the integrated area under each curve equals 1. Each patient's rate of change in eGFR while currently in each AER category is estimated from the general linear mixed model in Table 2 (the current albuminuria model). Note the range of substantially increased rates of decline in eGFR while subjects had macroalbuminuria relative to those while having normal albuminuria or microalbuminuria.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

Items 301–310 of 310

Metadata

Authors
Molitch, M. E., Steffes, M., Sun, W., Rutledge, B., Cleary, P., de Boer, I. H., Zinman, B., Lachin, J., & for the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Group
Affiliations
  • Northwestern University (US)
  • University of Minnesota (US)
  • George Washington University (US)
  • Weststat, Rockville, Maryland;
  • University of Washington, Seattle, Washington;
  • University of Toronto (CA)
Corresponding author
Cleary, Patricia
Venue
Diabetes Care
Published
2010-04-22
Volume
33
Issue
7
Pages
1536-1543
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2112283107
Cited by
306
References
31
Citations by year
2026: 6 · 2025: 10 · 2024: 15 · 2023: 13 · 2022: 25 · 2021: 19 · 2020: 17 · 2019: 25 · 2018: 23 · 2017: 17 · 2016: 17 · 2015: 24 · 2014: 33 · 2013: 23 · 2012: 22
FWCI
15.28
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
Keywords
type 1 diabetes, albuminuria, macroalbuminuria, microalbuminuria, urinary albumin excretion rate, chronic kidney disease, estimated glomerular filtration rate decline, renal failure, diabetic nephropathy, Diabetes Control and Complications Trial, kidney disease screening, glycemic control, blood pressure control
MeSH terms
Adult, Albuminuria, Creatinine, Diabetes Mellitus, Type 1, Diabetic Nephropathies, Female, Follow-Up Studies, Glomerular Filtration Rate, Humans, Male, Predictive Value of Tests, Risk Factors, Severity of Illness Index, Multicenter Studies as Topic, Incidence, Randomized Controlled Trials as Topic, Disease Progression, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.